Feb 22, 2022 · IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio’s Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol poly-kinase inhibitors.

Feb 22, 2022 · IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio’s Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with...

Feb 22, 2022 · IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells. ImmixBio anticipates filing an IND for IMX-120 in...

IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio’s Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol ...

Feb 22, 2022 · IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio's Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol poly-kinase inhibitors.

ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio’s path to clinical trials for IMX-120 in inflammatory bowel disease. The IBD market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019."

IMX-120: a GLUT1 inhibitors Drug, Initially developed by Immix Biopharma, Inc., Now, its global highest R&D status is Discontinued, Mechanism: GLUT1 inhibitors (Glucose transporter 1 inhibitors), Therapeutic Areas: Immune System Diseases,Digestive System Disorders.

IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio's Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol poly-kinase inhibitors.

Feb 22, 2022 · Immix Biopharma, Inc. (Nasdaq: IMMX) today announced that it has initiated Good Manufacturing Practice (GMP) manufacturing of IMX-120, a biologic for inflammatory bowel disease (IBD). ImmixBio ...

Feb 22, 2022 · IMX-120 is a Tissue-Specific Biologic™ built on ImmixBio’s Immune Normalization Technology™ for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol poly-kinase inhibitors.